ZYPREXA RELPREVV Drug Patent Profile
✉ Email this page to a colleague
When do Zyprexa Relprevv patents expire, and when can generic versions of Zyprexa Relprevv launch?
Zyprexa Relprevv is a drug marketed by Cheplapharm and is included in one NDA.
The generic ingredient in ZYPREXA RELPREVV is olanzapine pamoate. There are thirty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the olanzapine pamoate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZYPREXA RELPREVV?
- What are the global sales for ZYPREXA RELPREVV?
- What is Average Wholesale Price for ZYPREXA RELPREVV?
Summary for ZYPREXA RELPREVV
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 29 |
| Patent Applications: | 55 |
| Drug Prices: | Drug price information for ZYPREXA RELPREVV |
| DailyMed Link: | ZYPREXA RELPREVV at DailyMed |
US Patents and Regulatory Information for ZYPREXA RELPREVV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cheplapharm | ZYPREXA RELPREVV | olanzapine pamoate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 022173-001 | Dec 11, 2009 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cheplapharm | ZYPREXA RELPREVV | olanzapine pamoate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 022173-002 | Dec 11, 2009 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cheplapharm | ZYPREXA RELPREVV | olanzapine pamoate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 022173-003 | Dec 11, 2009 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZYPREXA RELPREVV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cheplapharm | ZYPREXA RELPREVV | olanzapine pamoate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 022173-001 | Dec 11, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Cheplapharm | ZYPREXA RELPREVV | olanzapine pamoate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 022173-002 | Dec 11, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| Cheplapharm | ZYPREXA RELPREVV | olanzapine pamoate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 022173-003 | Dec 11, 2009 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZYPREXA RELPREVV
See the table below for patents covering ZYPREXA RELPREVV around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Czech Republic | 302367 | 2-Methylthienobenzodiazepinový prípravek (2-Methyl-thieno-benzodiazepine formulation) | ⤷ Sign Up |
| China | 1239158 | ⤷ Sign Up | |
| Croatia | P20000181 | 2-METHYL-THIENO-BENZODIAZEPINE FORMULATION | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZYPREXA RELPREVV
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0454436 | 97C0012 | Belgium | ⤷ Sign Up | PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927 |
| 0454436 | C970015 | Netherlands | ⤷ Sign Up | PRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927 |
| 0454436 | SPC/GB96/058 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
